Qais Abu Ali, M.D., FACMG
Qais joined the executive team of Origin Biosciences as the vice president of clinical development, focused on rare and ultra-rare genetic diseases. He is a certified physician-geneticist by the American Board of Medical Genetics and Genomics, and holds active medical licenses in multiple states including CA and NY, as well as internationally in Jordan. Dr. Ali’s experience spans nearly 2 decades, in the U.S. and Middle East, combined, in internal medicine, clinical genetics, molecular diagnostics, and pharmaceutical and therapeutic fields including natural history and clinical survey studies as well as various phase clinical trials.
Most recently, Dr. Ali was the medical director of global clinical development at Ultragenyx Pharmaceutical and the medical lead for various ultra-rare genetic disease clinical programs, including the first treatment for mucopolysaccharidosis type VII that received approvals in the U.S., E.U. and Brazil, all within one year. Previously, Dr. Ali held various leadership and executive positions including lab co-director and medical director at the CLIA-certified CAP-accredited lab, GeneDx. He also ran a clinical practice and served as an assistant clinical investigator (assistant professor) at the National Institutes of Health. Dr. Ali completed two fellowships in clinical genetics and clinical molecular genetics at the National Institutes of Health and completed his internal medicine residency at Henry Ford Hospital.